- Home
- ENSC vs PAVM Comparison
ENSC vs PAVM Comparison
Compare ENSC & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- PAVM
- Stock Information
- Founded
- ENSC 2003
- PAVM 2014
- Country
- ENSC United States
- PAVM United States
- Employees
- ENSC N/A
- PAVM N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- ENSC Health Care
- PAVM Health Care
- Exchange
- ENSC Nasdaq
- PAVM Nasdaq
- Market Cap
- ENSC 7.9M
- PAVM 8.0M
- IPO Year
- ENSC N/A
- PAVM 2016
- Fundamental
- Price
- ENSC $5.40
- PAVM $0.79
- Analyst Decision
- ENSC
- PAVM Strong Buy
- Analyst Count
- ENSC 0
- PAVM 1
- Target Price
- ENSC N/A
- PAVM $19.00
- AVG Volume (30 Days)
- ENSC 26.4K
- PAVM 248.8K
- Earning Date
- ENSC 03-14-2025
- PAVM 03-25-2025
- Dividend Yield
- ENSC N/A
- PAVM N/A
- EPS Growth
- ENSC N/A
- PAVM N/A
- EPS
- ENSC N/A
- PAVM 0.53
- Revenue
- ENSC $4,421,404.00
- PAVM $4,034,000.00
- Revenue This Year
- ENSC $89.78
- PAVM $52.90
- Revenue Next Year
- ENSC N/A
- PAVM $248.84
- P/E Ratio
- ENSC N/A
- PAVM $1.50
- Revenue Growth
- ENSC 40.41
- PAVM 166.27
- 52 Week Low
- ENSC $2.12
- PAVM $0.57
- 52 Week High
- ENSC $14.67
- PAVM $3.50
- Technical
- Relative Strength Index (RSI)
- ENSC 35.78
- PAVM 60.82
- Support Level
- ENSC $5.34
- PAVM $0.73
- Resistance Level
- ENSC $6.14
- PAVM $0.90
- Average True Range (ATR)
- ENSC 0.43
- PAVM 0.08
- MACD
- ENSC -0.04
- PAVM 0.02
- Stochastic Oscillator
- ENSC 9.49
- PAVM 65.02
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.